← Leaderboards
Charles S Hemenway
Tulane University Of Louisiana
$4,448,480
Attributed
$8,432,229
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $694.1K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,432,229 · 9
By mechanism
R01$7,333,479 · 4
P20$712,289 · 4
K01$386,461 · 1
Top collaborators
- John Hackett Bushweller14 shared
- Nancy J Zeleznik-Le14 shared
- Maria Eugenia Figueroa8 shared
Others in their field
Top investigators on “Peptides”
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
- Michael W Weiner · Northern California Institute Res &Educ$78,425,041
- Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
- Rolf Apweiler · European Molecular Biology Laboratory$56,677,991
Research focus
PeptidesMll GeneMllt2 GeneLeukemiaMllt3 GeneGene ExpressionChimeric ProteinsComplexProteinsDrug DevelopmentLeukemogenesisGenesIn VitroIn VivoCellsC-TerminalChromosomal TranslocationHematopoietic Stem CellsGrantHematopoieticBaseBloodLinkAutomobile Driving
Grant awards (33)
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$589,759
R01 · FY2023 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$65,778
R01 · FY2023 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$589,759
R01 · FY2022 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$65,778
R01 · FY2022 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$601,794
R01 · FY2021 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$67,800
R01 · FY2021 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$617,133
R01 · FY2020 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$642,234
R01 · FY2019 · CA
Structure/Function of AF9 and MLL-AF9$466,785
R01 · FY2015 · CA
Structure/Function of AF9 and MLL-AF9$8,300
R01 · FY2015 · CA
Structure/Function of AF9 and MLL-AF9$452,783
R01 · FY2014 · CA
Structure/Function of AF9 and MLL-AF9$438,781
R01 · FY2013 · CA
Structure/Function of AF9 and MLL-AF9$466,788
R01 · FY2012 · CA
Targeted therapy for 11q23 acute leukemias$196,905
R01 · FY2012 · CA · contact PI
Structure/Function of AF9 and MLL-AF9$497,147
R01 · FY2011 · CA
Targeted therapy for 11q23 acute leukemias$196,905
R01 · FY2011 · CA · contact PI
Targeted therapy for 11q23 acute leukemias$202,994
R01 · FY2010 · CA · contact PI
Targeted therapy for 11q23 acute leukemias$202,994
R01 · FY2009 · CA · contact PI
Disrupting the AF4-AF9 protein complex in MLL leukemias.$129,195
R01 · FY2009 · CA · contact PI
Disrupting the AF4-AF9 protein complex in MLL leukemias.$129,195
R01 · FY2008 · CA · contact PI
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA$28,213
P20 · FY2008 · RR · contact PI
Targeted therapy for 11q23 acute leukemias.$93,107
R01 · FY2007 · CA · contact PI
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA$62,847
P20 · FY2007 · RR · contact PI
Targeted therapy for 11q23 acute leukemias.$195,765
R01 · FY2006 · CA · contact PI
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA$86,283
P20 · FY2006 · RR · contact PI
Targeted therapy for 11q23 acute leukemias.$14,850
R01 · FY2006 · CA · contact PI
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA$285,748
P20 · FY2005 · RR
Targeted therapy for 11q23 acute leukemias.$200,475
R01 · FY2005 · CA
TULANE CANCER GENETICS COBRE: INOVATIVE THERAPIES FOR T(4;11) LEUKEMIA$249,198
P20 · FY2004 · RR
Targeted therapy for 11q23 acute leukemias.$200,475
R01 · FY2004 · CA
BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION$140,282
K01 · FY2002 · CA
BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION$136,197
K01 · FY2001 · CA
BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION$109,982
K01 · FY2000 · CA